Navigation Links
LA BioMed's Dr. Patricia Dickson researching treatments for neurodegenerative disorders
Date:5/30/2012

LOS ANGELES (May 30, 2012) Patricia Dickson, M.D., principal investigator at The Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed), is co-principal investigator of a project that was just awarded a $5.5 million grant from the California Institute for Regenerative Medicine (CIRM). The goal of the project is to develop a stem cell based therapy for the treatment of mucopolysaccharidosis I (MPS I), a fatal pediatric lysosomal storage disease that causes neurodegeneration as well as defects in other major organ systems. Dr. Dickson is working with lead investigator Philip H. Schwartz, Ph.D., senior scientist at the CHOC Children's Research Institute and managing director of the facility's National Human Neural Stem Cell Resource.

For nearly a decade, Dr. Dickson's research at LA BioMed has focused on enzyme replacement therapy for mucopolysaccharidosis, a group of metabolic disorders caused by the absence or malfunctioning of enzymes needed to break down molecules - called glycosaminoglycans - which help build bone, cartilage, connective tissue and other essential parts of the body. As part of this study, she and her colleagues will begin with proof-of-principle experiments for MPS I.

"Dr. Dickson has been at the forefront of mucopolysaccharidosis research for many years, working tirelessly to help develop therapies for MPS I," said David I. Meyer, Ph.D., president and CEO of LA BioMed. "We congratulate her on her continued success, and for her role in this project which could be an important breakthrough for children suffering from neurodegenerative disorders."

"The unique aspect of this research is that it uses a single donor for the transplantation of stem cells into the body and the brain, which allows the best treatment for both physical and neurological disease and avoids rejection of neural stem cell grafts by the host immune system," said Dr. Dickson. "Pediatric neurodegenerative diseases are generally neglected in stem cell research, but stand the greatest chance of success. The high probability of success, along with the need to alleviate suffering in children, is why we believe the first applications of stem cell therapies should be for these kids."

Dr. Schwartz, Dr. Dickson and project collaborators are working to address two critical issues in the development of a therapeutic candidate based on stem cells: that early intervention is not only required but is indeed possible in this patient population, and that the concept of immune tolerance is also required, where the immune system is trained to attack only real threats in the body but not the body's own cells or tissues.

To date, there is still a significant unmet medical need to better impact and prevent the neurodegenerative processes in this disease. If successful in MPS I, this technique can be expanded to help treat other neurodegenerative disorders due to lysosomal storage.


'/>"/>

Contact: Diana Soltesz
diana@dsmmedia.com
818-592-6747
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed)
Source:Eurekalert

Related medicine news :

1. Sodexo Names Patricia Bellinger to North America Advisory Board
2. What Causes A Person To Be Mentally Ill? Author Who Has Spent Decades Researching Topic Says He Has the Answer
3. Global Basecamps Launches New Website: Researching and Booking Sustainable Travel Has Never Been Easier
4. Neuroimaging study may pave way for effective Alzheimers treatments
5. Charging less for more effective treatments could reduce health care costs while improving health
6. NIH grants to Childrens Hospital will advance novel stem cell treatments for blood disorders
7. Roseville Radiation Oncology Center (ROC) Redefines Efficiency With Elekta VMAT Radiotherapy Treatments
8. Two Sepsis Treatments Look Equally Effective
9. Heart Stem Cells Move Closer to Human Treatments
10. New Ankle Arthritis Treatments Help Boomers Stay Active
11. Larynx preservation treatments result in low instance of severe voice disability, nutritional dysfunction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... ... 2017 , ... John D'Eri, CEO of Rising Tide Car Wash , ... during the Autism Society of America 's 49th annual conference to be ... Foundation (DJFF) was founded in 2002 as the nation's first autism organization focused ...
(Date:6/20/2017)... , ... June 20, 2017 , ... ... patient’s bedside, would like to officially welcome Anthony Stanowski, DHA, FACHE to the ... Stanowski whose insight and expertise in healthcare will provide invaluable direction for the ...
(Date:6/20/2017)... ... ... The law firm of Momkus McCluskey Roberts LLC congratulates attorney Gerald ... Association’s Board of Directors. Cassioppi officially took on the leadership role during the DCBA’s ... McCluskey Roberts LLC attorney Stacey A. McCullough was also installed as the DCBA’s second ...
(Date:6/20/2017)... MD (PRWEB) , ... June 20, 2017 , ... As ... nation, the Society of Professional Benefit Administrators (SPBA) has provided input to the U.S. ... with Sens. Mitch McConnell (R - KY), Charles E. Schumer (D - NY) and ...
(Date:6/19/2017)... , ... June 19, 2017 , ... ... brand new operating rooms this month. These additions will expand the capabilities of ... state-of-the-art facilities. One operating room will be solely dedicated to pediatric operations, while ...
Breaking Medicine News(10 mins):
(Date:6/5/2017)... The Cincinnati location of ... (NYSE: DPLO), has been awarded a Top Workplaces 2017 ... Results are based on an employee survey administered by WorkplaceDynamics, ... improvement. The survey measures several aspects of workplace culture, including ... ...
(Date:6/1/2017)... BLUE BELL, Pa. , June 1, 2017 /PRNewswire/ ... Nutriceuticals (PRN) and Veterinarian Recommended Solutions (VRS), and KD ... direct investment in Nutriceutical Holdings by KD Pharma Group. ... Nutriceutical Holdings with the option to acquire the entire ... ideal partner in KD. They are committed to growing ...
(Date:5/29/2017)... AVIV, Israel, May 29, 2017  Cellect Biotechnology Ltd. ... innovative technology which enables the functional selection of stem ... results for the first quarter ended March 31 st ... with our accomplishments in the first quarter of 2017," ... first quarter, we announced the treatment of the first ...
Breaking Medicine Technology: